Truist Securities Reiterates Buy Rating on Regeneron Pharma (REGN)

January 13, 2025 11:15 AM EST Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $1,004.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login